Editors Choice
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
In 2018, durvalumab was approved by the U.S. Food and Drug Administration as consolidation immunotherapy for patients with stage III NSCLC after definitive chemoradiotherapy (CRT). However, whether durvalumab benefits patients with EGFR-mutated NSCLC remains unknown.
